Luke Simpson

Quality Project Manager at Abbott Dundee | previously @UoDCeTPD PROTAC Cell Biologist & @mrcppu @sapkota_mrcppu PhD

[Norbert Kraut @norbertkraut1]

Excited to share an analysis on “Therapeutic targeting of beta-catenin in cancer” published today in Molecular Cancer Therapeutics @MCT_AACR, an @AACR Journals publication, ahead of the American Association for Cancer Research D3 meeting #AACRdrugdev26

Mutations in CTNNB1 (encoding beta-catenin), together with recurrent genetic alterations affecting the WNT signaling pathway collectively occur in more than 10% of human cancers. Thus, the WNT/beta-catenin pathway represents an attractive drug target, but only a limited number of compounds have entered clinical trials. This Perspective highlights lessons learned and it assesses opportunities and challenges in the development of therapies that directly aim to target beta-catenin. We highlight recent progress based on novel approaches – including stabilized peptides, degraders and condensate modulators, suggesting that cracking this previously considered “undruggable” central oncogenic driver is becoming a reality.

Big thanks to my co-authors at @Boehringer Ingelheim, Paola Martinelli and Peter Repiscak, for great team work in putting this analysis together.

Link to paper (open access):
https://t.co/fFFUgHj5jM

[nature @Nature]

Nature research paper: Identification of an allosteric site on the E3 ligase adapter cereblon

https://t.co/3GC4n3eAm6

[Woo Lab @thewoolab]

Pour a glass of champagne AND red Bordeaux—Our newest work with @GSK and @scrippsresearch is out in @Nature, where we describe SB-405483, the first allosteric CRBN ligand which potentiates neosubstrate degradation. Congrats Vanessa and all authors! 🍷💫💐
https://t.co/MLj3VOgsOq

[Daniel Gerlach @gerlach_d]

Opening applications for a Principal Scientist, Computational Cancer Biology at @Boehringer!
Drive cutting‑edge computational oncology, advance MoA insights, shape biomarker‑driven patient selection, and turn multiomics + clinicogenomics into discoveries.
https://t.co/Y9UTSoO5b7

[Cell Chemical Biology @CellChemBiol]

Online now! Deciphering phosphorylation TACtics: Advances in phosphorylation targeting strategies and bifunctional modalities https://t.co/vLHtNhwn5k #chembiol

[MRC PPU @mrcppu]

Join us! Research Technician position available in Sapkota lab https://t.co/3wgV20nGZr

[Nur Kocatürk @nurkocaturk]

I am delighted to see our D2B approach for CNS-active degrader discovery is online . KH1 is identified as a rapid, potent and highly selective in vivo active chemical probe. For details: https://t.co/KFvnaxypL1
@FarnabyLab @dundeeuni @UoDCeTPD

[Cell Chemical Biology @CellChemBiol]

Online now! A method for the detection and enrichment of endogenous cereblon substrates https://t.co/tRIWBpexWo #chembiol

[Luke Simpson @lukemsimpson]

& to all the fantastic colleagues I had the pleasure to work with during this time! Keep continuing to #innovate, #collaborate & #inspire, and I look forward to seeing all the amazing science when it comes out! ✨

[Luke Simpson @lukemsimpson]

After an incredible 3.5 years, I recently finished my time at @UoDCeTPD, working as part of the CeTPD-Boehringer Ingelheim PROTAC collaboration team. A huge thank you to Kirsten, @farnaby84 & @alessiociulli for the opportunity to join the Team and all your guidance throughout,

[Centre for Targeted Protein Degradation @UoDCeTPD]

📖 The June-July Journal Club edition is out! Thanks to Aileen, Hiro, Ilaria and Mokhitli, great job editors! Don’t miss out on the latest news in TPD, have a look at the new edition of the Journal Club!

https://t.co/0R2sI6kdzu

#openaccess #TPD #journalclub @UoDLifeSciences

[Centre for Targeted Protein Degradation @UoDCeTPD]

Pleased to share Dr Nur Kocaturk has been awarded a Cross-Sector Experience Award from @acmedsci

This funding will allow them to collaborate with Promega Corp to co-develop a new cellular ligand finding platform for intractable disease related proteins.

[Luke Simpson @lukemsimpson]

@nurkocaturk @acmedsci Woohoo! Huge well done, Nur, very well deserved! 💪✨

[Arvinas @ArvinasInc]

#NEWS: We're proud to share the @US_FDA has accepted our first-ever New Drug Application with @Pfizer for an investigational PROTAC ER degrader for patients with ESR1-mutated, ER+/HER2- advanced or metastatic #BreastCancer.

Read the full release: https://t.co/JIKx7PRYXW

[Katherine A Donovan @kdonovan1008]

Heads up for those working in ubiquitin biology and targeted protein degradation—Lorne Ubiquitin 2025 is happening 20–23 November in Lorne, Victoria, Australia.
Late abstracts are still being accepted—worth checking out!!! 🦘🦘🦘

[Alejandro Correa Sáez @ACorreasa]

Excited to share with you our latest preprint on SMARCA2/4 degraders! at the @UoDCeTPD in collaboration with #GeorgWinter´s lab. Here, we show how a Molecular Glue Degrader can covalently and redundantly recruit DCAF16 and FBXO22 to degrade SMARCA2/4
https://t.co/DmM53sXYie

[Michael Erb @Michael_A_Erb]

New work introducing PCIPs, heterobifunctional chemical inducers of proximity that inhibit DNA repair by recruiting BET proteins to PARP2. Great work uncovering a new form of event-driven pharmacology by Bryce/Eric/Erin and the rest of the team. (1/3)
https://t.co/SHg4JURfyQ

[Katherine A Donovan @kdonovan1008]

🧩 New paper out in Nature Communications!

"Unveiling the hidden interactome of CRBN molecular glues"
Huge thanks to our incredible team and collaborators who made this possible!
📖 Read the full open-access article here: https://t.co/iuTyDM24Vs

[Katherine A Donovan @kdonovan1008]

Our proteomics group is looking for a Scientist  who is excited to push the boundaries of chemoproteomics and interactomics at Dana‑Farber!

Apply at the link or message me with questions! https://t.co/csqFoClQQo

[UoD Life Sciences @UoDLifeSciences]

Delighted to share that a project 'Green PROTACs – Enabling Small Molecule (Re)programming and Manipulation of Plant Biology' by Dr Piers Hemsley @Hemsley_Lab, Professor @alessiociulli and Dr @HajkDrost has been funded through this scheme.